CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice